Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons

Nature Neuroscience volume 26, pages 1417–1428 (2023)Cite this article

Subjects

Abstract

Elevated dopamine transmission in psychosis is assumed to unbalance striatal output through D1- and D2-receptor-expressing spiny-projection neurons (SPNs). Antipsychotic drugs are thought to re-balance this output by blocking D2 receptors (D2Rs). In this study, we found that amphetamine-driven dopamine release unbalanced D1-SPN and D2-SPN Ca2+ activity in mice, but that antipsychotic efficacy was associated with the reversal of abnormal D1-SPN, rather than D2-SPN, dynamics, even for drugs that are D2R selective or lacking any dopamine receptor affinity. By contrast, a clinically ineffective drug normalized D2-SPN dynamics but exacerbated D1-SPN dynamics under hyperdopaminergic conditions. Consistent with antipsychotic effect, selective D1-SPN inhibition attenuated amphetamine-driven changes in locomotion, sensorimotor gating and hallucination-like perception. Notably, antipsychotic efficacy correlated with the selective inhibition of D1-SPNs only under hyperdopaminergic conditions—a dopamine-state-dependence exhibited by D1R partial agonism but not non-antipsychotic D1R antagonists. Our findings provide new insights into antipsychotic drug mechanism and reveal an important role for D1-SPN modulation.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Effects of amphetamine treatment on D1-SPN/D2-SPN Ca2+ activity in freely behaving mice.
Fig. 2: Effects of antipsychotic drugs or a failed drug candidate on behavior and D1-SPN/D2-SPN dynamics.
Fig. 3: Effects of drugs lacking dopamine receptor affinity on behavior and D1-SPN/D2-SPN dynamics.
Fig. 4: Inhibiting D1-SPNs is sufficient to rescue amphetamine-driven behaviors.
Fig. 5: Effects of D1R-targeted compounds on behavior and D1-SPN/D2-SPN dynamics.
Fig. 6: Antipsychotic efficacy is better explained by a drug’s effects on D1-SPN than D2-SPN activity levels.

Data availability

We have provided Source Data underlying each figure and statistical conclusion. Source data are provided with this paper.

Code availability

The software code used to process our Ca2+ movies (https://bahanonu.github.io/ciatah/) as well as MARS (https://github.com/neuroethology/MARS) and the training code that we used for behavioral classification (https://github.com/neuroethology/MARS_Developer) and manual annotation (https://github.com/neuroethology/bentoMAT) are freely available online. The code used to analyze individual behaviors is available at https://github.com/arinpamukcu/parkerlab/.

References

  1. Carlsson, A. & Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.) 20, 140–144 (1963).

    CAS  PubMed  Google Scholar 

  2. Creese, I., Burt, D. R. & Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483 (1976).

    CAS  PubMed  Google Scholar 

  3. Matthysse, S. Dopamine and the pharmacology of schizophrenia: the state of the evidence. J. Psychiatr. Res. 11, 107–113 (1974).

    CAS  PubMed  Google Scholar 

  4. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238–246 (1989).

    CAS  PubMed  Google Scholar 

  5. Davies, M. A., Sheffler, D. J. & Roth, B. L. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 10, 317–336 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Kramer, M. S., Last, B., Getson, A. & Reines, S. A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry 54, 567–572 (1997).

    CAS  PubMed  Google Scholar 

  7. Allen, J. A. et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl Acad. Sci. USA 108, 18488–18493 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Menniti, F. S., Chappie, T. A. & Schmidt, C. J. PDE10A inhibitors—clinical failure or window into antipsychotic drug action? Front. Neurosci. 14, 600178 (2021).

    PubMed  PubMed Central  Google Scholar 

  9. Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394, 939–951 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. McCutcheon, R. A., Abi-Dargham, A. & Howes, O. D. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 42, 205–220 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M. & Caron, M. G. Dopamine receptors: from structure to function. Physiol. Rev. 78, 189–225 (1998).

    CAS  PubMed  Google Scholar 

  12. Mink, J. W. The basal ganglia: focused selection and inhibition of competing motor programs. Prog. Neurobiol. 50, 381–425 (1996).

    CAS  PubMed  Google Scholar 

  13. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353–359 (2004).

    CAS  PubMed  Google Scholar 

  14. Schmidt, C. J. et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 325, 681–690 (2008).

    CAS  PubMed  Google Scholar 

  15. Menniti, F. S., Chappie, T. A. & Schmidt, C. J. PDE10A inhibitors—clinical failure or window into antipsychotic drug action? Front. Neurosci. 14, 600178 (2020).

    PubMed  Google Scholar 

  16. Parker, J. G. et al. Diametric neural ensemble dynamics in parkinsonian and dyskinetic states. Nature 557, 177–182 (2018).

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Klaus, A. et al. The spatiotemporal organization of the striatum encodes action space. Neuron 96, 949 (2017).

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Brannan, S. K. et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N. Engl. J. Med. 384, 717–726 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Foster, D. J. et al. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron 91, 1244–1252 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Dedic, N. et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J. Pharmacol. Exp. Ther. 371, 1–14 (2019).

    CAS  PubMed  Google Scholar 

  21. Schmack, K., Bosc, M., Ott, T., Sturgill, J. F. & Kepecs, A. Striatal dopamine mediates hallucination-like perception in mice. Science 372, eabf4740 (2021).

    CAS  PubMed  Google Scholar 

  22. Karlsson, P. et al. Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl.) 121, 309–316 (1995).

    CAS  PubMed  Google Scholar 

  23. Kahlig, K. M. et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc. Natl Acad. Sci. USA 102, 3495–3500 (2005).

    CAS  PubMed  PubMed Central  Google Scholar 

  24. DeMartinis, N. 3rd et al. A proof-of-concept study evaluating the phosphodiesterase 10A inhibitor PF-02545920 in the adjunctive treatment of suboptimally controlled symptoms of schizophrenia. J. Clin. Psychopharmacol. 39, 318–328 (2019).

    CAS  PubMed  Google Scholar 

  25. Geyer, M. A., Krebs-Thomson, K., Braff, D. L. & Swerdlow, N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl.) 156, 117–154 (2001).

    CAS  PubMed  Google Scholar 

  26. Segalin, C. et al. The Mouse Action Recognition System (MARS) software pipeline for automated analysis of social behaviors in mice. eLife 10, e63720 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Ince, E., Ciliax, B. J. & Levey, A. I. Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons. Synapse 27, 357–366 (1997).

  28. Halff, E. F., Rutigliano, G., Garcia-Hidalgo, A. & Howes, O. D. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 46, 60–74 (2023).

    CAS  PubMed  Google Scholar 

  29. Begni, V. et al. Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856. Int. J. Mol. Sci. 22, 4119 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Woolley, M. L., Carter, H. J., Gartlon, J. E., Watson, J. M. & Dawson, L. A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur. J. Pharmacol. 603, 147–149 (2009).

    CAS  PubMed  Google Scholar 

  31. Roth, B. L. DREADDs for neuroscientists. Neuron 89, 683–694 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Nagai, Y. et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nat. Neurosci. 23, 1157–1167 (2020).

    CAS  PubMed  Google Scholar 

  33. Doherty, J. M. et al. Contributions of dopamine D1, D2, and D3 receptor subtypes to the disruptive effects of cocaine on prepulse inhibition in mice. Neuropsychopharmacology 33, 2648–2656 (2008).

    CAS  PubMed  Google Scholar 

  34. Wheeler, D. S. et al. Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine. Proc. Natl Acad. Sci. USA. 112, E7138–E7147 (2015).

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Tirelli, E. & Terry, P. Biphasic locomotor effects of the dopamine D1 agonist SKF 38393 and their attenuation in non-habituated mice. Psychopharmacology (Berl.) 110, 69–75 (1993).

    CAS  PubMed  Google Scholar 

  36. Li, P., Snyder, G. L. & Vanover, K. E. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr. Top. Med. Chem. 16, 3385–3403 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Yan, Z., Song, W. J. & Surmeier, J. D2 dopamine receptors reduce N-type Ca2+ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. J. Neurophysiol. 77, 1003–1015 (1997).

    CAS  PubMed  Google Scholar 

  38. Straub, C., Tritsch, N. X., Hagan, N. A., Gu, C. & Sabatini, B. L. Multiphasic modulation of cholinergic interneurons by nigrostriatal afferents. J. Neurosci. 34, 8557–8569 (2014).

    PubMed  PubMed Central  Google Scholar 

  39. Centonze, D. et al. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J. Neurosci. 23, 6245–6254 (2003).

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Lacey, M. G., Mercuri, N. B. & North, R. A. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J. Physiol. 392, 397–416 (1987).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Bamford, N. S. et al. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42, 653–663 (2004).

    CAS  PubMed  Google Scholar 

  42. Hersch, S. M. et al. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15, 5222–5237 (1995).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Bevan, M. D. et al. Selective innervation of neostriatal interneurons by a subclass of neuron in the globus pallidus of the rat. J. Neurosci. 18, 9438–9452 (1998).

  44. Hoover, B. R. & Marshall, J. F. Molecular, chemical, and anatomical characterization of globus pallidus dopamine D2 receptor mRNA-containing neurons. Synapse 52, 100–113 (2004).

  45. Wiltschko, A. B., Pettibone, J. R. & Berke, J. D. Opposite effects of stimulant and antipsychotic drugs on striatal fast-spiking interneurons. Neuropsychopharmacology 35, 1261–1270 (2010).

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Fenton, W. S. Prevalence of spontaneous dyskinesia in schizophrenia. J. Clin. Psychiatry 61, 10–14 (2000).

    PubMed  Google Scholar 

  47. Shen, W., Flajolet, M., Greengard, P. & Surmeier, D. J. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321, 848–851 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Dobbs, L. K. et al. Dopamine regulation of lateral inhibition between striatal neurons gates the stimulant actions of cocaine. Neuron 90, 1100–1113 (2016).

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Shin, J. H., Song, M., Paik, S. B. & Jung, M. W. Spatial organization of functional clusters representing reward and movement information in the striatal direct and indirect pathways. Proc. Natl Acad. Sci. USA 117, 27004–27015 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Meltzer, H. Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 64, 393–406 (2013).

    CAS  PubMed  Google Scholar 

  51. Kapur, S., Zipursky, R., Jones, C., Remington, G. & Houle, S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157, 514–520 (2000).

    CAS  PubMed  Google Scholar 

  52. Kapur, S., Zipursky, R. B. & Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156, 286–293 (1999).

    CAS  PubMed  Google Scholar 

  53. Kane, J., Honigfeld, G., Singer, J. & Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789–796 (1988).

    CAS  PubMed  Google Scholar 

  54. Hagger, C. et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry 34, 702–712 (1993).

    CAS  PubMed  Google Scholar 

  55. Tauscher, J. et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 161, 1620–1625 (2004).

    PubMed  Google Scholar 

  56. Seeger, T. F. et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res. 985, 113–126 (2003).

    CAS  PubMed  Google Scholar 

  57. Yael, D. et al. Haloperidol-induced changes in neuronal activity in the striatum of the freely moving rat. Front. Syst. Neurosci. 7, 110 (2013).

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Taverna, S., Ilijic, E. & Surmeier, D. J. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson’s disease. J. Neurosci. 28, 5504–5512 (2008).

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Gainetdinov, R. R., Hoener, M. C. & Berry, M. D. Trace amines and their receptors. Pharmacol. Rev. 70, 549–620 (2018).

    CAS  PubMed  Google Scholar 

  60. Laruelle, M. & Abi-Dargham, A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13, 358–371 (1999).

    CAS  PubMed  Google Scholar 

  61. Gessa, G. L., Canu, A., Del Zompo, M., Burrai, C. & Serra, G. Lack of acute antipsychotic effect of Sch 23390, a selective dopamine D1 receptor antagonist. Lancet 337, 854–855 (1991).

    CAS  PubMed  Google Scholar 

  62. Astrup, A. et al. Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. Obesity (Silver Spring) 15, 1717–1731 (2007).

    CAS  PubMed  Google Scholar 

  63. Lieberman, J. A. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18, 251–267 (2004).

    CAS  PubMed  Google Scholar 

  64. Slifstein, M. et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 72, 316–324 (2015).

    PubMed  PubMed Central  Google Scholar 

  65. Stahl, S. M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors. J. Clin. Psychiatry 62, 841–842 (2001).

    CAS  PubMed  Google Scholar 

  66. Hurd, Y. L., Suzuki, M. & Sedvall, G. C. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J. Chem. Neuroanat. 22, 127–137 (2001).

    CAS  PubMed  Google Scholar 

  67. Brozoski, T. J., Brown, R. M., Rosvold, H. E. & Goldman, P. S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205, 929–932 (1979).

    CAS  PubMed  Google Scholar 

  68. Arnsten, A. F., Cai, J. X., Murphy, B. L. & Goldman-Rakic, P. S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl.) 116, 143–151 (1994).

    CAS  PubMed  Google Scholar 

  69. Moya, N. A. et al. The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia. Neuropsychopharmacology 48, 690–699 (2022).

  70. Pinto, L. et al. An accumulation-of-evidence task using visual pulses for mice navigating in virtual reality. Front. Behav. Neurosci. 12, 36 (2018).

    PubMed  PubMed Central  Google Scholar 

  71. Zhou, P. et al. Efficient and accurate extraction of in vivo calcium signals from microendoscopic video data. eLife 7, e28728 (2018).

    PubMed  PubMed Central  Google Scholar 

  72. Corder, G. et al. An amygdalar neural ensemble that encodes the unpleasantness of pain. Science 363, 276–281 (2019).

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank B. Ahanonu for assistance in data processing, P. J. Conn for providing VU0467154, J. I. Sanders and A. Kepecs for guidance in setting up the task to measure HALIP and L. Pinto for help with psychometric modeling of behavior. S.Y., B.Y., J.D.A., M.M.M., S.W.F. and J.G.P. were funded by National Institute of Mental Health (NIMH) K01MH113132, National Institute of Neurological Disorders and Stroke R01NS122840 and the Whitehall Foundation. A.P. and A.K. were funded by Aligning Science Across Parkinson’s ASAP-020551 through the Michael J. Fox Foundation for Parkinson’s Research. N.-H.Y. and A.C. were funded by NIMH R01MH099114.

Author information

Authors and Affiliations

  1. Department of Neuroscience, Northwestern University, Chicago, IL, USA

    Seongsik Yun, Ben Yang, Justin D. Anair, Madison M. Martin, Stefan W. Fleps, Arin Pamukcu, Nai-Hsing Yeh, Anis Contractor, Ann Kennedy & Jones G. Parker

Authors
  1. Seongsik Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ben Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Justin D. Anair
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Madison M. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefan W. Fleps
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arin Pamukcu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nai-Hsing Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anis Contractor
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ann Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jones G. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

S.Y. performed all imaging, behavior experiments and histological experiments. B.Y. performed surgeries and assisted with imaging experiments. J.D.A. performed surgeries and assisted with the HALIP experiment. M.M.M. and S.W.F. performed mouse surgeries and oversaw mouse breeding. A.P. and A.K. performed analyses of pose estimation and the rates of activity associated with specific behaviors. N.-H.Y. and A.C. conducted electrophysiology experiments. S.Y. and J.G.P. designed all experiments, performed all data analysis and wrote the manuscript, with input from the co-authors.

Corresponding author

Correspondence to Jones G. Parker.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Neuroscience thanks Chris Langmead and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Histological validation and characterization of normal D1-/D2-SPN ensemble dynamics and hM4Di-mCherry functionality.

a, Representative coronal brain sections of DMS and substantia nigra reticulata (SNr) from GCaMP7f-expressing D1- or A2A-Cre mice (green: anti-GFP; blue: DAPI nuclear stain; scale bar: 1 mm). White lines indicate the position of the implanted microendoscope and boundaries of brain areas. b, Ca2+ event rates in D1- and D2-SPNs across increasing running speed bins. c, Co-activity (Jaccard index) of D1- or D2-SPN pairs during movement (locomotor speed >= 0.5 cm·s−1) versus the separation of cell pairs, normalized to temporally shuffled datasets (dashed line). Cyan shading indicates proximal (25–125 μm) cell pairs. d, Co-activity of proximal D1- and D2-SPN pairs across increasing running speed bins, normalized to temporally shuffled comparisons (dashed line). e, Ca2+ event amplitudes in D1- and D2-SPNs across increasing locomotor speed bins (for b–e, N = 18 D1-Cre and N = 17 A2A-Cre mice; data were averaged across all recordings following vehicle only treatment; **P < 0.01 comparing D1-SPNs to D2-SPNs; Two-way ANOVA with Holm-Sidak’s multiple comparison test). f, Representative coronal brain sections of DMS and subtantia nigra from hM4Di-mCherry expressing D1-Cre mice (red: mCherry; blue: DAPI nuclear stain; scale bar: 1 mm). g, We performed patch-clamp electrophysiological recordings from hM4Di-mCherry-expressing neurons in the DMS of D1-Cre mice. h, Representative traces of action potential responses to 250 pA current injection. i, Number of evoked action potentials following vehicle, DCZ or CNO treatment (N = 4 cells; *P < 0.05 compared to vehicle treatment; One-way ANOVA with Holm-Sidak’s multiple comparison test). All data are mean ± s.e.m. Exact P values for these and all other analyses are in the Supplementary Table. All N values refer to number of mice for all figures unless otherwise specified.

Source data

Extended Data Fig. 2 Antipsychotic drug dose selection based on locomotor activity.

a–c, Locomotor activity in untethered, C57BL6/J mice during 15 min following vehicle or drug treatment and 45 min following amphetamine treatment (see Fig. 2a). Effects of haloperidol, olanzapine, clozapine, or MP-10 (a), xanomeline, VU0467154, or SEP-363856 (b), and SKF39393, SCH23390, or SCH39166 (c) on baseline and amphetamine-driven locomotion. The ‘low’ and ‘high’ doses we subsequently used for Ca2+ imaging experiments are indicated in red. Data are expressed as mean ± s.e.m. (****P < 10−4 ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle treatment; ####P < 10−4 and ##P < 10−2 compared to vehicle + amphetamine treatment; One-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 3 Effects of drug treatments on D1-/ D2-SPN dynamics under baseline conditions.

a–f, Bar plots depict the mean ± s.e.m Ca2+ event rates (a, c, e) and proximal co-activity (b, d, f) of D1- and D2-SPNs, normalized to values following vehicle only treatment during periods of rest (left) or movement (right) following haloperidol, olanzapine, clozapine, or MP-10 (a, b), xanomeline, VU0467154, or SEP-363856 (c, d), and SKF39393, SCH23390, or SCH39166 (e, f) treatment. Heat maps display either the effects of drugs on the ratio of D1- to D2-SPN Ca2+ event rates (D1/D2; left in a, c, e) or the ratio of drug to vehicle treatment on the rates (Drug/Vehicle; right in a, c, e) or proximal co-activity (b, d, f) of D1- and D2-SPN activity during periods or rest (left) or movement (right) (****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 compared to vehicle treatment; One-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 4 Antipsychotic drug effects on D1-/D2-SPN Ca2+ dynamics under baseline conditions as a function of locomotor speed.

a, b, Drug effects on D1- (a) and D2-SPN (b) Ca2+ event rates across different speed bins following vehicle or drug only treatment. c, d, Drug effects on the proximal co-activity of D1- (c) and D2-SPNs (d) across different speed bins following vehicle or drug only treatment. Data are represented as mean ± s.e.m. (****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle treatment; Two-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 5 Drug effects on D1-/D2-SPN Ca2+ event amplitudes under normal and hyperdopaminergic conditions.

a–c, Mean ± s.e.m. Ca2+ event amplitudes of D1- and D2-SPNs across all speeds following treatment with haloperidol, olanzapine, clozapine, or MP-10 (a), xanomeline, VU0467154, or SEP-363856 (b), and SKF39393, SCH23390, or SCH39166 (c), normalized to values following vehicle only treatment. Data are from periods before (top) or after (bottom) amphetamine treatment. Heat maps depict the mean D1- and D2-SPN Ca2+ event amplitudes, normalized to values following vehicle only treatment (Drug/Vehicle) and the vehicle-normalized values, normalized to the corresponding value following vehicle + amphetamine treatment (Drug/Amph; ****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle treatment; ####P < 10−4, ###P < 10−3, ##P < 10−2 and #P < 0.05 compared vehicle + amphetamine treatment; One-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 6 Antipsychotic drug effects on D1-/D2-SPN Ca2+ dynamics as a function of locomotor speed under hyperdopaminergic conditions.

a, b, Drug effects on Ca2+ event rates of D1- (a) and D2-SPNs (b) across different speed bins following vehicle or drug + amphetamine treatment. c, d, Drug effects on the proximal co-activity of D1- (c) and D2-SPNs (d) across different speed bins following vehicle or drug + amphetamine treatment. Data are represented as mean ± s.e.m. (****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle + amphetamine treatment; Two-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 7 Longitudinal stability of D1-/D2-SPN dynamics under normal and hyperdopaminergic conditions.

a, b, Ca2+ event rates (left), proximal co-activity (middle) and Ca2+ event amplitudes (right) of D1- (top) and D2-SPNs (bottom) across all locomotor speed bins and drug treatment blocks following vehicle (a) or amphetamine only (b) treatment. Data are represented as mean ± s.e.m. (***P < 10−3, **P < 10−2 and *P < 0.05 compared to naive; One-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 8 Drug effects on the time spent engaged in specific behaviors and their associated D1- and D2-SPN activity levels.

a, b, Proportion of time engaged in specific behaviors (a) and the D1- and D2-SPN Ca2+ event rates associated with those behaviors (b) following vehicle or amphetamine treatment. c, The predicted and actually observed Ca2+ event rates of D1- and D2-SPNs following amphetamine treatment during periods of rest or movement, normalized to values following vehicle treatment. Predicted values were computed from a weighted average of the event rates associated with each behavior following vehicle treatment in (b) and the proportion of time spent engaged in each behavior following amphetamine treatment in (a), where the specific behaviors were grouped into resting and moving types for comparison to the observed data here and reported in the main text (Figs. 1 and 2). d, Proportion of time spent in categorized resting and moving behaviors following vehicle, vehicle + amphetamine, or drug + amphetamine treatment. e, The predicted and actually observed Ca2+ event rates of D1- and D2-SPNs following drug + amphetamine treatment during periods of rest or movement, normalized to values following vehicle treatment. Predicted values were computed from the data in (b) and (d) as described in (c). All data are expressed as mean ± s.e.m. (****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 compared to vehicle treatment (a, b) or predicted values (c, e); two-tailed Wilcoxon signed-rank test; ++++P < 10−4 and +++P < 10−3 comparing vehicle to vehicle + amphetamine treatment and ####P < 10−4, ###P < 10−3, ##P < 10−2 and #P < 0.05 comparing drug + amphetamine to vehicle + amphetamine treatment (d); One-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 9 Dopamine receptor-independent drug effects on D1-/D2-SPN Ca2+ dynamics as a function of locomotor speed under normal and hyperdopaminergic conditions.

a, b, Drug effects on D1- (a) and D2-SPN (b) Ca2+ event rates across different speed bins following vehicle or drug only treatment. c, d, Drug effects on the proximal co-activity of D1- (c) and D2-SPNs (d) across different speed bins following vehicle or drug only treatment. e, f, Drug effects on Ca2+ event rates of D1- (e) and D2-SPNs (f) across different speed bins following vehicle or drug + amphetamine treatment. g, h, Drug effects on the proximal co-activity of D1- (g) and D2-SPNs (h) across different speed bins following vehicle or drug + amphetamine treatment. Data are represented as mean ± s.e.m. (****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle treatment (a–d) or to vehicle + amphetamine treatment (e–h); Two-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Extended Data Fig. 10 D1R-targeted drug effects on D1-/D2-SPN Ca2+ dynamics as a function of locomotor speed under normal and hyperdopaminergic conditions.

a, b, Drug effects on D1- (a) and D2-SPN (b) Ca2+ event rates across different speed bins following vehicle or drug only treatment. c, d, Drug effects on the proximal co-activity of D1- (c) and D2-SPNs (d) across different speed bins following vehicle or drug only treatment. e, f, Drug effects on Ca2+ event rates of D1- (e) and D2-SPNs (f) across different speed bins following vehicle or drug + amphetamine treatment. g, h, Drug effects on the proximal co-activity of D1- (g) and D2-SPNs (h) across different speed bins following vehicle or drug + amphetamine treatment. Data are represented as mean ± s.e.m. (****P < 10−4, ***P < 10−3, **P < 10−2 and *P < 0.05 for comparison to vehicle treatment (a–d) or to vehicle + amphetamine treatment (e–h); Two-way ANOVA with Holm-Sidak’s multiple comparison test).

Source data

Supplementary information

Reporting Summary

Supplementary Table 1

Summary table of n and P values of all statistical comparisons.

Source data

Source Data Fig. 1

Statistical source data.

Source Data Fig. 2

Statistical source data.

Source Data Fig. 3

Statistical source data.

Source Data Fig. 4

Statistical source data.

Source Data Fig. 5

Statistical source data.

Source Data Fig. 6

Statistical source data.

Source Data Extended Data Fig./Table 1

Statistical source data.

Source Data Extended Data Fig./Table 2

Statistical source data.

Source Data Extended Data Fig./Table 3

Statistical source data.

Source Data Extended Data Fig./Table 4

Statistical source data.

Source Data Extended Data Fig./Table 5

Statistical source data.

Source Data Extended Data Fig./Table 6

Statistical source data.

Source Data Extended Data Fig./Table 7

Statistical source data.

Source Data Extended Data Fig./Table 8

Statistical source data.

Source Data Extended Data Fig./Table 9

Statistical source data.

Source Data Extended Data Fig./Table 10

Statistical source data.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yun, S., Yang, B., Anair, J.D. et al. Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons. Nat Neurosci 26, 1417–1428 (2023). https://doi.org/10.1038/s41593-023-01390-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41593-023-01390-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing